1-7 of 7
Tycel J. Phillips
Close
Sort by
Journal Articles

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis

Clinical Trials & Observations
Michael L Wang, Tadeusz Robak, Prof., Kami J Maddocks, Tycel J. Phillips, Stephen Douglas Smith, David Gallinson, Roser Calvo, MD PhD, Chuan-Chuan Wun, Veerendra Munugalavadla, Wojciech Jurczak
Journal: Blood Advances
Blood Adv bloodadvances.2023012424.
https://doi.org/10.1182/bloodadvances.2023012424
Published: 2024
Includes: Supplemental data
Journal Articles

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Clinical Trials & Observations
Tycel J. Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson
Journal: Blood Advances
Blood Adv (2024) 8 (4): 867–877.
https://doi.org/10.1182/bloodadvances.2023010648
Published: 2024
Includes: Supplemental data
Journal Articles

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Adam J. Olszewski, Tycel J. Phillips, Marc S. Hoffmann, Philippe Armand, Tae Min Kim, Dok Hyun Yoon, Amitkumar Mehta, Richard Greil, Jason Westin, Izidore S. Lossos, Javier L. Munoz, Jason Sit, Michael C. Wei, Annie Yang, Vivian Chen, Enkhtsetseg Purev, Donald L. Yee, Ulrich Jaeger
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6055–6065.
https://doi.org/10.1182/bloodadvances.2023010840
Published: 2023
Includes: Supplemental data
Journal Articles

Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma

Clinical Trials & Observations
Tycel J. Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa, Philip Boonstra, Tera Lynn Mayer, Victoria Nachar, Ryan A. Wilcox, Shannon A. Carty, Yasmin H. Karimi, Zaneta Nikolovska-Coleska, Mark S. Kaminski, Alex F. Herrera, Kami Maddocks, Leslie Popplewell, Alexey V. Danilov
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4518–4527.
https://doi.org/10.1182/bloodadvances.2023009992
Published: 2023
Includes: Supplemental data
Journal Articles

Durable responses with ALK inhibitors for primary refractory anaplastic lymphoma Kinase-positive large B-cell lymphoma

Radhika Takiar, Tycel J. Phillips
Journal: Blood Advances
Blood Adv (2023) 7 (12): 2912–2916.
https://doi.org/10.1182/bloodadvances.2022007537
Published: 2023
Journal Articles

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma

Clinical Trials & Observations
Constantine S. Tam, Stephen Opat, David Simpson, Gavin Cull, Javier Munoz, Tycel J. Phillips, Won Seog Kim, Simon Rule, Siminder Kaur Atwal, Rachel Wei, William Novotny, Jane Huang, Michael Wang, Judith Trotman
Journal: Blood Advances
Blood Adv (2021) 5 (12): 2577–2585.
https://doi.org/10.1182/bloodadvances.2020004074
Published: 2021
Includes: Supplemental data
Journal Articles

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael L. Leblanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel J. Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3132–3135.
https://doi.org/10.1182/bloodadvances.2019000526
Published: 2019